Dexcom (DXCM) Long-Term Debt Repayments (2013 - 2023)

Dexcom's (DXCM) quarterly Long-Term Debt Repayments came in at $136.8 million in Q4 2023, up 7947.06% on a QoQ basis from $1.7 million in Q2 2016.

Dexcom (DXCM) Long-Term Debt Repayments (2013 - 2023) Analysis & Trends

Dexcom (DXCM) has 5 years of Long-Term Debt Repayments data on file, last reported at $136.8 million in Q4 2023.

On a quarterly basis, Long-Term Debt Repayments changed N/A year-over-year to $136.8 million in Q4 2023; TTM through Dec 2024 was $136.8 million, a 0.0% change from a year earlier, with the FY2023 full-year figure at $787.3 million, changed N/A from the prior year.
Long-Term Debt Repayments for Q4 2023 stood at $136.8 million, up from $1.7 million in the prior quarter.
Over the last five years, Long-Term Debt Repayments for DXCM reached as high as $136.8 million in Q4 2023 and fell as low as $136.8 million in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Repayments (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn	1.42 Bn
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn	1.00 Bn
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn	-
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn	-
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn	-
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn	-
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn	-64.39 Mn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn	-
9	Smith & Nephew	25.80 Bn	25.22 Bn	-	-
10	Steris	20.59 Bn	20.16 Bn	697.10 Mn	-

Download Data